Your browser doesn't support javascript.
loading
BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
Herbert, Katharine; Binet, Romuald; Lambert, Jean-Philippe; Louphrasitthiphol, Pakavarin; Kalkavan, Halime; Sesma-Sanz, Laura; Robles-Espinoza, Carla Daniela; Sarkar, Sovan; Suer, Eda; Andrews, Sarah; Chauhan, Jagat; Roberts, Nicola D; Middleton, Mark R; Gingras, Anne-Claude; Masson, Jean-Yves; Larue, Lionel; Falletta, Paola; Goding, Colin R.
Afiliação
  • Herbert K; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Binet R; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Lambert JP; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada.
  • Louphrasitthiphol P; Department of Molecular Medicine, Cancer Research Centre, Université Laval, Quebec G1V 0A6, Canada; CHU de Québec Research Center, CHUL, Quebec G1V 4G2, Canada.
  • Kalkavan H; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Sesma-Sanz L; Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
  • Robles-Espinoza CD; Genome Stability Laboratory, CHU de Oncology Division, Québec Research Center, Québec City, Quebec G1R 3S3, Canada.
  • Sarkar S; Department of Molecular Biology, Medical Biochemistry, and Pathology, Laval University Cancer Research Center, Québec City, Quebec G1V 0A6, Canada.
  • Suer E; Laboratorio Internacional de Investigación Sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro 76230, Mexico.
  • Andrews S; Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, United Kingdom.
  • Chauhan J; Department of Oncology, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Roberts ND; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Middleton MR; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Gingras AC; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Masson JY; The Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, United Kingdom.
  • Larue L; Department of Oncology, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Falletta P; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada.
  • Goding CR; Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
Genes Dev ; 33(5-6): 310-332, 2019 03 01.
Article em En | MEDLINE | ID: mdl-30804224
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Apoptose / Proteínas de Homeodomínio / Fatores do Domínio POU / Reparo do DNA por Junção de Extremidades / Melanoma / Mutação Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Apoptose / Proteínas de Homeodomínio / Fatores do Domínio POU / Reparo do DNA por Junção de Extremidades / Melanoma / Mutação Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article